Palisade Bio, INC S-1 registration statements

Palisade Bio, Inc. filed an S-1MEF registration statement to offer up to $24.5 million in common stock and warrants to fund its operations.

Palisade Bio, a clinical-stage biopharmaceutical company, is offering up to 147 million shares and pre-funded warrants to raise approximately $92.4 million for advancing its lead IBD candidate, PALI-2108, despite ongoing Nasdaq listing concerns and going concern doubt.

Palisade Bio, a clinical-stage biopharmaceutical company, announced a public offering of common stock and pre-funded warrants to raise approximately $8.9 million, following positive Phase 1 clinical trial results for its lead IBD candidate, PALI-2108.

Clinical-stage biopharmaceutical company Palisade Bio, Inc. is offering up to 2,857,142 Class A Units and Class B Units to raise capital for its Phase 1 clinical trial and other development activities.

Clinical-stage biopharmaceutical company Palisade Bio, Inc. is offering 2,427,184 shares of common stock and pre-funded warrants to purchase up to 2,427,184 shares, alongside representative warrants for up to 145,631 shares, to raise capital for clinical trials and operations.

Palisade Bio has filed an amendment to its registration statement for a public offering of common stock and pre-funded warrants, aiming to raise up to $5.75 million to support its clinical development programs.

Palisade Bio is launching a public offering of common stock and pre-funded warrants to raise capital for its PALI-2108 clinical trial and other research initiatives.